KR950002755A - 워트마닌 및 그의 유사체에 의한 포스파티딜이노시톨 3-키나제의 억제 - Google Patents

워트마닌 및 그의 유사체에 의한 포스파티딜이노시톨 3-키나제의 억제 Download PDF

Info

Publication number
KR950002755A
KR950002755A KR1019940017228A KR19940017228A KR950002755A KR 950002755 A KR950002755 A KR 950002755A KR 1019940017228 A KR1019940017228 A KR 1019940017228A KR 19940017228 A KR19940017228 A KR 19940017228A KR 950002755 A KR950002755 A KR 950002755A
Authority
KR
South Korea
Prior art keywords
phosphatidylinositol
kinase
analogs
wortmannin
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019940017228A
Other languages
English (en)
Korean (ko)
Inventor
본조우클리안 로잔느
포위스 가드
존 블라호스 크리스
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
잔느 엠. 클리스피
디 아리조나 보드 오브 레전츠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니, 잔느 엠. 클리스피, 디 아리조나 보드 오브 레전츠 filed Critical 피터 지. 스트링거
Publication of KR950002755A publication Critical patent/KR950002755A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1019940017228A 1993-07-19 1994-07-18 워트마닌 및 그의 유사체에 의한 포스파티딜이노시톨 3-키나제의 억제 Withdrawn KR950002755A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/094,279 US5378725A (en) 1993-07-19 1993-07-19 Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US08/094,279 1993-07-19

Publications (1)

Publication Number Publication Date
KR950002755A true KR950002755A (ko) 1995-02-16

Family

ID=22244209

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940017228A Withdrawn KR950002755A (ko) 1993-07-19 1994-07-18 워트마닌 및 그의 유사체에 의한 포스파티딜이노시톨 3-키나제의 억제

Country Status (16)

Country Link
US (1) US5378725A (enExample)
EP (1) EP0635268A1 (enExample)
JP (1) JPH0753370A (enExample)
KR (1) KR950002755A (enExample)
CN (1) CN1111127A (enExample)
AU (1) AU678831B2 (enExample)
CA (1) CA2128046A1 (enExample)
CZ (1) CZ283806B6 (enExample)
HU (1) HUT67667A (enExample)
IL (1) IL110325A0 (enExample)
NO (1) NO942641L (enExample)
PH (1) PH30794A (enExample)
PL (1) PL304317A1 (enExample)
RU (1) RU94026082A (enExample)
TW (1) TW287102B (enExample)
ZA (1) ZA945103B (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468773A (en) * 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5504103A (en) * 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US7863429B2 (en) * 1995-12-21 2011-01-04 Qlt Inc. Treatment of inflammatory diseases including psoriasis
US5910417A (en) * 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
US7670767B1 (en) 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
AU770896C (en) * 1998-09-29 2006-09-07 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
ATE333896T1 (de) * 1998-03-24 2006-08-15 Chugai Pharmaceutical Co Ltd Vaskularisierungsinhibitoren
US6413773B1 (en) * 1998-06-01 2002-07-02 The Regents Of The University Of California Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
ATE556713T1 (de) * 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2001024826A2 (en) * 1999-10-06 2001-04-12 The Brigham And Women's Hospital, Inc. Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
AU6513701A (en) * 2000-05-30 2001-12-11 Advanced Res & Tech Inst Compositions and methods for identifying agents which modulate pten function andpi-3 kinase pathways
US7235523B2 (en) * 2001-04-13 2007-06-26 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US6703414B2 (en) * 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) * 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
CA2491555C (en) * 2002-07-10 2012-09-11 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
GB0304632D0 (en) * 2003-02-28 2003-04-02 Proxara Biotechnology Ltd Method
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
AU2004217699B2 (en) * 2003-03-07 2008-07-03 Gamida-Cell Ltd. Expansion of renewable stem cell populations using modulators of PI 3-kinase
JP2006524289A (ja) * 2003-04-23 2006-10-26 ワイス・ホールディングズ・コーポレイション Ｐｅｇ−ワートマニンコンジュゲート
PT1636585E (pt) * 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
IL161903A0 (en) * 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
NZ544920A (en) * 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
JP2007501836A (ja) 2003-08-13 2007-02-01 クドス ファーマシューティカルズ リミテッド アミノピロン類及びａｔｍ阻害剤としてのその使用
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
EP1799812A4 (en) * 2004-09-16 2009-09-09 Gamida Cell Ltd EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS
CN101061111A (zh) 2004-09-20 2007-10-24 库多斯药物有限公司 Dna－pk抑制剂
US7666901B2 (en) * 2004-10-13 2010-02-23 Wyeth Analogs of 17-hydroxywortmannin as PI3K inhibitors
CN100369632C (zh) * 2004-10-14 2008-02-20 孔庆忠 抗癌药物组合物
CN1875959B (zh) * 2004-10-14 2010-05-12 孔庆忠 一种抗癌药物组合物
TW200638938A (en) 2005-02-09 2006-11-16 Kudos Pharm Ltd ATM inhibitors
AU2006214190A1 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
AR053358A1 (es) 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
WO2006119569A1 (en) * 2005-05-11 2006-11-16 Genetic Technologies Limtied Methods of enriching fetal cells
CA2609387A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
JP2007063205A (ja) * 2005-08-31 2007-03-15 Japan Science & Technology Agency 神経因性疼痛治療剤
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
JP2010509316A (ja) * 2006-11-09 2010-03-25 ガミダ セル リミテッド 末梢血管疾患を治療するためのエクスビボ培養された造血細胞の使用
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20100109416A1 (en) * 2008-11-03 2010-05-06 Jones Margaret L Adjustable safety harness
ES2674719T3 (es) 2008-11-13 2018-07-03 Gilead Calistoga Llc Terapias para neoplasias hematológicas
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
MX2011011036A (es) * 2009-04-20 2012-01-20 Gilead Calistoga Llc Metodos de tratamiento para tumores solidos.
KR20120049281A (ko) 2009-07-21 2012-05-16 길리아드 칼리스토가 엘엘씨 Ｐｉ３ｋ 억제제를 이용한 간 장애의 치료
BRPI1107182B1 (pt) * 2011-12-29 2022-03-08 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
US20150064273A1 (en) 2012-02-13 2015-03-05 Gamida-Cell Ltd. Mesenchymal Stem Cells Conditioned Medium and Methods of Generating and Using the Same
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
JP2017502021A (ja) 2013-12-20 2017-01-19 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤のためのプロセス方法
CA2934534A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
CN104774239B (zh) * 2015-03-13 2017-01-04 暨南大学 多节孢绿胶霉素类化合物及其用途
CN107058137B (zh) * 2017-06-14 2020-02-07 海正药业(杭州)有限公司 一种渥曼青霉及其生产渥曼青霉素的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668222A (en) * 1969-05-14 1972-06-06 Sandoz Ltd 11-desacetoxy-wortmannin
US4988682A (en) * 1989-02-03 1991-01-29 University Of Pittsburgh Myo-inositol analogs and method for their use
JPH0328948A (ja) * 1989-06-27 1991-02-07 Nec Corp 入出力制御装置の動作状態情報収集方式

Also Published As

Publication number Publication date
RU94026082A (ru) 1996-05-20
HUT67667A (en) 1995-04-28
HU9402128D0 (en) 1994-09-28
TW287102B (enExample) 1996-10-01
PL304317A1 (en) 1995-01-23
CA2128046A1 (en) 1995-01-20
CZ283806B6 (cs) 1998-06-17
JPH0753370A (ja) 1995-02-28
NO942641D0 (no) 1994-07-14
NO942641L (no) 1995-01-20
ZA945103B (en) 1996-03-27
CZ169294A3 (en) 1995-02-15
CN1111127A (zh) 1995-11-08
IL110325A0 (en) 1994-10-21
AU678831B2 (en) 1997-06-12
US5378725A (en) 1995-01-03
AU6754094A (en) 1995-01-27
EP0635268A1 (en) 1995-01-25
PH30794A (en) 1997-10-17

Similar Documents

Publication Publication Date Title
KR950002755A (ko) 워트마닌 및 그의 유사체에 의한 포스파티딜이노시톨 3-키나제의 억제
RU2221781C2 (ru) Тиолсульфоновые соединения в качестве ингибитора матриксной металлопротеазы и способы лечения
KR900011772A (ko) 3-(1,2,5,6-테트라하이드로피리딜)피롤로피리딘
KR960700045A (ko) 혈관신생 저해제 및 신규 화합물
KR920021506A (ko) 19-노르 비타민 d 화합물 합성용 중간체
KR870002158A (ko) Hmg-coa 환원효소 억제제의 제조방법
KR950010890A (ko) 폐경기 증후군의 치료방법
DE3761307D1 (de) Herstellung von fibraten.
KR950031068A (ko) 골다공증의 복합 치료
FI880494A0 (fi) Nya 5-alkoxi-2,4 -diaminoalkylbenzener samt dessa innehaollande haorfaergningsmedel.
RU93005334A (ru) Производные стероидов для лечения гипертрофии предстательной железы, способ их получения, использование, фармкомпозиция
KR880009910A (ko) 리폭시게네이즈 억제 화합물
PT81855B (pt) Processo de preparacao de arilciclobutilalquilaminas e de composicoes farmaceuticas que as contem
KR950010891A (ko) 내성 종양을 치료하는 방법
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR890006590A (ko) 4-아미노피리딘 유도체
RU93036551A (ru) Способ получения ii-кето-стероидных производных
RU94016198A (ru) Производные тетразолсодержащего амида, смесь их изомеров или отдельные изомеры и соли
SE8102047L (sv) Inhibitorer av kolesterolbiosyntes, deras framstellning och anvendning
KR910018344A (ko) 종양 질환 치료를 위한 엽산염 및 항엽산염과의 디플루오로글루탐산 공액체
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
ES2172294T3 (es) Nuevos derivados del 1-indanol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
KR920702890A (ko) 포지티브 레지스트 조성물
KR890009890A (ko) 하이드록시 피리미딘의 아실 유도체
KR890008121A (ko) 로다닌 유도체 및 약제학적 조성물

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19940718

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid